Dyslipidaemia, hypercoagulability and the metabolic syndrome
| dc.contributor.author | Kakafika, A. I. | en |
| dc.contributor.author | Liberopoulos, E. N. | en |
| dc.contributor.author | Karagiannis, A. | en |
| dc.contributor.author | Athyros, V. G. | en |
| dc.contributor.author | Mikhailidis, D. P. | en |
| dc.date.accessioned | 2015-11-24T19:23:26Z | |
| dc.date.available | 2015-11-24T19:23:26Z | |
| dc.identifier.issn | 1570-1611 | - |
| dc.identifier.uri | https://olympias.lib.uoi.gr/jspui/handle/123456789/22307 | |
| dc.rights | Default Licence | - |
| dc.subject | Adipose Tissue/metabolism | en |
| dc.subject | Adiposity | en |
| dc.subject | Animals | en |
| dc.subject | Aspirin/therapeutic use | en |
| dc.subject | Cardiovascular Diseases/blood/drug therapy/*etiology/metabolism | en |
| dc.subject | Cholesterol, HDL/blood | en |
| dc.subject | Clofibric Acid/therapeutic use | en |
| dc.subject | Dyslipidemias/blood/*complications/drug therapy/metabolism | en |
| dc.subject | Factor VII/metabolism | en |
| dc.subject | Fibrinolytic Agents/therapeutic use | en |
| dc.subject | Humans | en |
| dc.subject | Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use | en |
| dc.subject | Hypolipidemic Agents/therapeutic use | en |
| dc.subject | Inflammation Mediators/metabolism | en |
| dc.subject | Insulin Resistance | en |
| dc.subject | Life Style | en |
| dc.subject | Lipoproteins, LDL/blood | en |
| dc.subject | Metabolic Syndrome X/blood/*complications/drug therapy/metabolism | en |
| dc.subject | Obesity/blood/complications/drug therapy/metabolism | en |
| dc.subject | Plasminogen Activator Inhibitor 1/blood/metabolism | en |
| dc.subject | Thrombophilia/blood/*complications/drug therapy/metabolism | en |
| dc.subject | Triglycerides/blood | en |
| dc.subject | von Willebrand Factor/metabolism | en |
| dc.title | Dyslipidaemia, hypercoagulability and the metabolic syndrome | en |
| heal.abstract | The metabolic syndrome is a clustering of risk factors including central obesity, insulin resistance, dyslipidaemia and hypertension. This syndrome is associated with increased risk of cardiovascular disease and is a common early abnormality in the development of type 2 diabetes. The pathogenesis of the syndrome has multiple origins. Obesity and sedentary lifestyle coupled with genetic factors interact to produce the syndrome. Here, we consider two components of the metabolic syndrome, dyslipidaemia and hypercoagulability. | en |
| heal.access | campus | - |
| heal.fullTextAvailability | TRUE | - |
| heal.identifier.secondary | http://www.ncbi.nlm.nih.gov/pubmed/16842135 | - |
| heal.journalName | Curr Vasc Pharmacol | en |
| heal.journalType | peer-reviewed | - |
| heal.language | en | - |
| heal.publicationDate | 2006 | - |
| heal.recordProvider | Πανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικής | el |
| heal.type | journalArticle | - |
| heal.type.el | Άρθρο Περιοδικού | el |
| heal.type.en | Journal article | en |
Αρχεία
Φάκελος/Πακέτο αδειών
1 - 1 of 1
Φόρτωση...
- Ονομα:
- license.txt
- Μέγεθος:
- 1.74 KB
- Μορφότυπο:
- Item-specific license agreed upon to submission
- Περιγραφή: